GSK cuts 40% of China sales reps after bribery scandal

Shanghai

GLAXOSMITHKLINE Plc has cut 40 per cent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record US$490 million fine in 2014.

The British firm is gambling on a new, cleaner image to reboot its performance and reputation with doctors and consumers, China head Herve Gisserot told Reuters at the group's Shanghai headquarters.